As per MRFR analysis, the US Point of Care Glucose Testing Market Size was estimated at 764.11 (USD Million) in 2023. The US Point of Care Glucose Testing Market Industry is expected to grow from 803.07(USD Million) in 2024 to 1,389.19 (USD Million) by 2035. The US Point of Care Glucose Testing Market CAGR (growth rate) is expected to be around 5.108% during the forecast period (2025 - 2035).
The US Point of Care Glucose Testing Market is witnessing significant trends driven by the increasing prevalence of diabetes across the nation. As per the Centers for Disease Control and Prevention (CDC), millions of Americans are diagnosed with diabetes, which has heightened the need for accessible and efficient glucose monitoring solutions. Key market drivers include the rising demand for diabetes management tools, advances in technology, and the growing emphasis on preventive healthcare. Healthcare providers are looking for ways to streamline testing processes, which has led to innovations in testing devices that provide rapid results with minimal patient discomfort.
Opportunities also exist for manufacturers to explore integration with mobile health applications, allowing for more comprehensive patient data management and real-time monitoring. Additionally, partnerships with home healthcare services can create avenues for distributing point-of-care testing devices in non-traditional settings, further increasing their accessibility. Recently, there has been a noticeable trend toward user-friendly devices that cater to a diverse range of populations, including elderly patients and individuals with limited health literacy.
As more individuals seek to take control of their health, the demand for at-home and portable glucose testing devices is anticipated to grow.This trend indicates a broader shift toward patient-centered care, where empowering patients with real-time data plays a crucial role. Overall, the US Point of Care Glucose Testing Market is evolving rapidly, with advancements supporting not just the testing process but also the overall management of diabetes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of diabetes in the United States is a significant driver for the US Point of Care Glucose Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, had diabetes in 2020. This alarming increase showcases a serious health crisis that necessitates constant glucose monitoring, which propels the demand for point of care glucose testing devices.Leading companies like Abbott Laboratories and Roche Diagnostics are responding to this surge by enhancing their product offerings and investing in technology for more accurate and user-friendly glucose meters.
As the population ages and lifestyle diseases become more common, the number of diabetic patients is projected to rise, driving further growth in the glucose testing market. This trend is expected to increase the market's valuation significantly over the next decade.
Advancements in technology are revolutionizing the US Point of Care Glucose Testing Market Industry. The integration of smartphone connectivity, cloud-based data storage, and artificial intelligence are facilitating easier glucose monitoring and management. A report by the National Institutes of Health (NIH) suggests that digital health technologies can improve patient outcomes and compliance rates significantly. Prominent market players such as Dexcom and Johnson & Johnson are at the forefront of this innovation, introducing devices that provide real-time data and remote monitoring capabilities.These advancements not only enhance patient engagement but also improve overall clinical decision-making, considerably escalating the demand for advanced testing systems in the US.
The growing preference for home healthcare solutions among patients is another critical driver for the US Point of Care Glucose Testing Market Industry. The COVID-19 pandemic has shifted patient behaviors significantly, with more individuals opting for remote monitoring to minimize hospital visits. A study published by the American Hospital Association indicates that there was a 20% increase in home health care services utilization from April to July 2020.Companies like LifeScan and Ascensia Diabetes Care are capitalizing on this trend by providing easy-to-use, portable glucose testing devices, ensuring that patients can manage their diabetes effectively from home. This shift not only enhances the quality of life for patients but also fosters a growing market for at-home healthcare products.
The US Point of Care Glucose Testing Market is robustly categorized into various product types, including Lancing Devices, Strips, and Blood-Glucose Meters, each playing a vital role in diabetes management. Lancing Devices are essential tools that enable individuals to obtain blood samples painlessly, facilitating regular monitoring of glucose levels. Their convenience and user-friendly design contribute significantly to patient adherence to testing protocols. Strips, another critical component, are used in tandem with Blood-Glucose Meters to provide accurate glucose readings from blood samples.The innovation within this segment focuses on enhancing precision and reducing the time required for results, which is crucial for effective diabetes management.
Blood-Glucose Meters serve as the primary interface for individuals with diabetes, offering the capability to display glucose readings and trends over time. Their advancement in technology, including features like connectivity to mobile applications and cloud storage, empowers diabetics to track their health more efficiently and make informed decisions about their diet and medication.The growing prevalence of diabetes in the US, alongside an increasing awareness and focus on preventive healthcare, drives demand across these product types.
Market growth is further fueled by innovations such as smart glucose meters and continuous monitoring systems that promote proactive health management. The US Point of Care Glucose Testing Market segmentation reflects the ongoing evolution in diabetes care, where convenience and accuracy remain paramount, thereby suggesting a bright outlook for these indispensable product types.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Application segment of the US Point of Care Glucose Testing Market is primarily focused on the management of diabetes, particularly Type-1 and Type-2 Diabetes, which are critical health issues in the United States. The growing prevalence of these diabetes types drives innovative solutions in glucose monitoring, facilitating timely and accurate readings. Type-1 Diabetes, often diagnosed in children and young adults, requires continuous management, which enhances the demand for advanced Point of Care testing solutions. Conversely, Type-2 Diabetes, more common among adults, is influenced by lifestyle factors, thereby necessitating regular glucose monitoring for effective disease management.The importance of educational initiatives and healthcare accessibility in the US further underscores the significance of this segmentconsumers increasingly seek easy-to-use glucose monitoring devices that can integrate seamlessly into their daily routines, making management more manageable.
Consequently, the application of these testing technologies in clinical settings and home environments is expanding, reflecting the growing awareness of diabetes management among healthcare providers and patients alike. The US Point of Care Glucose Testing Market data reveals a tendency toward developing portable devices, emphasizing the convenience and real-time capabilities needed in diabetes healthcare strategies.Overall, advancements in technology and the rising focus on early diagnosis and personalized care significantly bolster the potential of this market segment.
The US Point of Care Glucose Testing Market presents a diverse array of end users, which play critical roles in the overall healthcare landscape. Hospitals traditionally serve as major settings for glucose monitoring, offering rapid test results crucial for immediate patient care. Clinics also contribute significantly, catering to the growing demand for diabetic patient management and routine check-ups, thus enhancing accessibility to glucose testing. Home care settings have emerged notably, driven by an increasing trend towards home healthcare solutions, allowing patients to manage their diabetes conveniently.This shift is supported by technological advancements and an aging population requiring continuous glucose monitoring. Other end users encompass a variety of healthcare environments, each playing unique roles in enabling effective glucose management.
With the rise in diabetes prevalence in the US, the segmentation within the US Point of Care Glucose Testing Market reflects not only the importance of these settings but also the increasing demand for personalized healthcare, further emphasizing the need for efficient and accessible glucose testing solutions.
The US Point of Care Glucose Testing Market is characterized by a rapidly evolving landscape driven by technological advancements, patient-centered healthcare approaches, and an increasing prevalence of diabetes. This market comprises various devices and technologies designed to provide instant blood glucose testing at the point of care. Competitors in this space continuously strive to innovate by introducing new products that offer improved accuracy, faster results, and user-friendly interfaces. As the demand for quick and effective diabetes management solutions grows, companies are leveraging strategic partnerships, investments in research and development, and aggressive marketing strategies to enhance their market presence and capture a broader segment of the consumer base.
Nova Biomedical has established a significant presence in the US Point of Care Glucose Testing Market, thanks to its comprehensive portfolio of glucose monitoring devices known for their accuracy and reliability. The company’s strength lies in its commitment to innovation, continuously developing advanced technologies that enhance the efficiency of glucose testing. Nova Biomedical's devices cater to various settings, including hospitals and private practices, making them versatile options for healthcare professionals. Their focus on user-centric design ensures that these devices are easy to operate, providing healthcare providers with rapid and precise results that are essential for effective patient management. Furthermore, Nova Biomedical maintains a strong customer support system, which is crucial in building trust and loyalty among healthcare practitioners.
Roche Diagnostics has a firm foothold in the Point of Care Glucose Testing Market within the US, offering a diverse range of products and services tailored for efficient diabetes care. The company's key offerings include accurate blood glucose meters and diagnostic kits designed to facilitate seamless patient testing. Roche Diagnostics is known for its commitment to research and development, which enables them to introduce cutting-edge testing technologies that set industry standards. The company's strengths lie in its extensive distribution network and established relationships within the healthcare community, which enhance its market presence. Roche Diagnostics has also pursued strategic mergers and acquisitions to expand its capabilities and enrich its product lineup, thereby reinforcing its position in the US market while addressing the increasing needs of diabetes management among patients and healthcare providers.
Recent developments in the US Point of Care Glucose Testing Market have shown steady growth, propelled by innovations and increasing demand for rapid testing solutions. In August 2023, Abbott Laboratories announced the launch of a new version of its Freestyle Libre system, aimed at enhancing user experience and providing real-time glucose monitoring for patients. Meanwhile, Roche Diagnostics unveiled advancements in their Accu-Chek line, focusing on improved accuracy and ease of use. In terms of mergers and acquisitions, a notable move was Medtronic's acquisition of Mazor Robotics in September 2022, which is expected to bolster their diabetes management portfolio.
The demand for seamless technology integration in diabetes management has led to collaborations, such as Dexcom partnering with Ascensia Diabetes Care for enhanced data management solutions. Furthermore, the market is seeing significant investments, with Becton Dickinson and Company committing to research and development to innovate their testing devices. This ongoing emphasis on technological improvement is likely shaping the landscape of the Point of Care Glucose Testing Market in the US, contributing to its rapid evolution and enhancing patient care efficacy.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 764.11(USD Million) |
| MARKET SIZE 2024 | 803.07(USD Million) |
| MARKET SIZE 2035 | 1389.19(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.108% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Nova Biomedical, Roche Diagnostics, Medtronic, Abbott Laboratories, Ascensia Diabetes Care, Dexcom, HSO Medical, Thermo Fisher Scientific, Becton Dickinson and Company, Zevia, Trividia Health, LifeScan, StarLabs, Bayer AG |
| SEGMENTS COVERED | Product Type, Application, End User |
| KEY MARKET OPPORTUNITIES | Telehealth integration expansion, Home testing kits demand, Continuous glucose monitoring advancements, Diabetes management software development, Emerging markets penetration |
| KEY MARKET DYNAMICS | growing diabetic population, increasing home testing, technological advancements, regulatory support, rising healthcare costs |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Point of Care Glucose Testing Market is expected to be valued at 803.07 million USD in 2024.
By 2035, the US Point of Care Glucose Testing Market is projected to reach a value of 1389.19 million USD.
The US Point of Care Glucose Testing Market is expected to grow at a CAGR of 5.108 percent from 2025 to 2035.
Among the product types, strips hold a significant market share, valued at 345.0 million USD in 2024.
The lancing devices segment is expected to be valued at 466.23 million USD by 2035.
Key players in the market include Nova Biomedical, Roche Diagnostics, and Abbott Laboratories.
The blood-glucose meter segment is expected to be valued at 188.07 million USD in 2024.
Growth drivers include the rising prevalence of diabetes and advancements in glucose testing technologies.
Challenges may include regulatory hurdles and competition from alternative diabetes management solutions.
There are significant opportunities for growth through innovation in product development and expanding market reach.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
